Chemokines in CSF of Alzheimer's disease patients
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Some studies have linked the presence of chemokines to the early stages of Alzheimer's disease (AD). Then, the identification of these mediators may contribute to diagnosis. Our objective was to evaluate the levels of beta-amyloid (BA), tau, phospho-tau (p-tau) and chemokines (CCL2, CXCL8 and CXCL10) in the cerebrospinal fluid (CSF) of patients with AD and healthy controls. The correlation of these markers with clinical parameters was also evaluated. The levels of p-tau were higher in AD compared to controls, while the tau/p-tau ratio was decreased. The expression of CCL2 was increased in AD. A positive correlation was observed between BA levels and all chemokines studied, and between CCL2 and p-tau levels. Our results suggest that levels of CCL2 in CSF are involved in the pathogenesis of AD and it may be an additional useful biomarker for monitoring disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What is cognitive reserve? Theory and research application of the reserve concept
STERN, Y. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702813248 · Cited by 3,951
Cognitive Reserve and Alzheimer Disease
Stern, Y. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213815.20177.19 · Cited by 838 · cited 1×
“The levels of beta-amyloid, tau and phospho-tau were determined in the CSF using the following kits: Innotest® β-Amyloid(1-42); Innotest® phospho-tau (181P) e Innotest®htauAg from Innogenetics (Gent, Belgium).”
MethodNeuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · cited 1×
“The levels of beta-amyloid, tau and phospho-tau were determined in the CSF using the following kits: Innotest® β-Amyloid(1-42); Innotest® phospho-tau (181P) e Innotest®htauAg from Innogenetics (Gent, Belgium).”
MethodMechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Intrathecal inflammation precedes development of Alzheimer's disease
Tarkowski, E. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1200 · Cited by 501 · cited 1×
“The levels of beta-amyloid, tau and phospho-tau were determined in the CSF using the following kits: Innotest® β-Amyloid(1-42); Innotest® phospho-tau (181P) e Innotest®htauAg from Innogenetics (Gent, Belgium).”
MethodAlonso, A. D. C., Grundke-Iqbal, I., Barra, H. S., & Iqbal, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.298 · Cited by 437
The network and the remodeling theories of aging: historical background and new perspectives
Franceschi, C., Valensin, S., Bonafè, M., Paolisso, G., Yashin, A. I., Monti, D., & De Benedictis, G. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00172-8 · Cited by 335 · cited 1×
“The levels of beta-amyloid, tau and phospho-tau were determined in the CSF using the following kits: Innotest® β-Amyloid(1-42); Innotest® phospho-tau (181P) e Innotest®htauAg from Innogenetics (Gent, Belgium).”
MethodISHIZUKA, K., KIMURA, T., IGATA‐YI, R., KATSURAGI, S., TAKAMATSU, J., & MIYAKAWA, T. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02375.x · Cited by 245 · cited 1×
“The levels of beta-amyloid, tau and phospho-tau were determined in the CSF using the following kits: Innotest® β-Amyloid(1-42); Innotest® phospho-tau (181P) e Innotest®htauAg from Innogenetics (Gent, Belgium).”
MethodBermejo, P., Martín-Aragón, S., Benedí, J., Susín, C., Felici, E., Gil, P., Ribera, J. M., & Villar, Á. M. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.02.002 · Cited by 178
Cited by
MCP-1: Function, regulation, and involvement in disease
Singh, S., Anshita, D., & Ravichandiran, V. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107598 · Cited by 883
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
“), CCL2 (ref.(225)) and chitotriosidase(226,227).”
Brosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8657-1 · Cited by 447
Lai, K. S. P., Liu, C. S., Rau, A., Lanctôt, K. L., Köhler, C. A., Pakosh, M., Carvalho, A. F., & Herrmann, N. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316201 · Cited by 433
Inflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427
Metadata
- Authors
- Corrêa, J. D., Starling, D., Teixeira, A. L., Caramelli, P., & Silva, T. A.
- Venue
- Arquivos de Neuro-Psiquiatria
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2011-06
- Volume
- 69
- Issue
- 3
- Pages
- 455-459
- ISSN
- 0004-282X (ISSN-L)
- OpenAlex
- W2033468757
- Cited by
- 79
- References
- 12
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemokines in CSF of Alzheimer's disease patients. https://app.cochat.ai/papers/10.1590/s0004-282x2011000400009
- The paper
- Corrêa, J. D., Starling, D., Teixeira, A. L., Caramelli, P., & Silva, T. A. (2011). Chemokines in CSF of Alzheimer's disease patients. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2011000400009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.